Agenus Inc. (NASDAQ:AGEN – Get Free Report) has been assigned an average rating of “Hold” from the six research firms that are presently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.50.
AGEN has been the subject of a number of research analyst reports. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Robert W. Baird lowered shares of Agenus from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $8.00 in a research report on Friday, July 19th. B. Riley dropped their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $7.00 price target (up previously from $3.00) on shares of Agenus in a report on Friday, July 19th. Finally, William Blair downgraded shares of Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th.
Check Out Our Latest Stock Report on Agenus
Institutional Trading of Agenus
Agenus Stock Up 5.6 %
NASDAQ AGEN opened at $6.26 on Friday. Agenus has a 52 week low of $4.41 and a 52 week high of $27.20. The company has a 50 day moving average price of $7.24 and a 200 day moving average price of $10.59. The firm has a market cap of $135.03 million, a PE ratio of -0.49 and a beta of 1.36.
Agenus (NASDAQ:AGEN – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to analyst estimates of $64.73 million. During the same quarter in the prior year, the company earned ($4.00) earnings per share. On average, equities research analysts anticipate that Agenus will post -10.87 earnings per share for the current fiscal year.
Agenus Company Profile
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
- Five stocks we like better than Agenus
- Breakout Stocks: What They Are and How to Identify Them
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Top Stocks Investing in 5G Technology
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- Most active stocks: Dollar volume vs share volume
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.